Business Wire

SKEMA and EADA Create a Double-Degree BBA in Barcelona

Share

SKEMA Business School and EADA Business School have signed an agreement to launch a new joint double-degree BBA programme "SKEMA X EADA Global BBA" in Barcelona, where EADA operates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006004/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Official signing of the partnership between SKEMA and EADA on 20 September 2021 from SKEMA Business School’s Grand Paris Campus. From left to right: Patrice Houdayer, Director of Programmes, International and Student Life, Koke Pursals, Chairman of the Board of Directors of the EADA Foundation, Alice Guilhon, SKEMA’s Dean & Executive President, and Jordi Diaz, EADA’s Dean. (Photo: Business Wire)

Through this alliance, SKEMA intends to develop a new European base from EADA's Barcelona campus. EADA will benefit from the presence of SKEMA’s campuses in five continents. At the same time, the two schools also aim to open this new four-year post-baccalaureate programme to candidates from Spanish-speaking countries.

"This post-baccalaureate double-degree programme is a new opportunity to develop SKEMA’s brand in the European continent and South America with EADA. It also offers our students in the SKEMA Global BBA – a programme which has 50% international students representing more than 60 different nationalities – the possibility of studying on the EADA campus and immersing themselves in the global city of Barcelona, with its ultra-dynamic economic centre, where they will be able to follow the sustainable innovation specialisation," explains Patrice Houdayer, Director of Programmes, International and Student Life at SKEMA Business School.

"As part of its development, EADA wanted to enter the field of post-baccalaureate BBA programmes, by favouring a partnership with a school that is highly recognised internationally. This is possible thanks to SKEMA, which will design a programme with us that meets the best international BBA standards, and which will confer the degree of bachelor and the visa," says Jordi Diaz, Dean at EADA.

From September 2022, students in the new EADA X SKEMA Global BBA double-degree programme will be able to spend the first two years on the EADA campus in Barcelona, then go on a mobility programme in the third year on one of SKEMA's seven campuses across the world, and then spend their fourth year either in Barcelona or on one of SKEMA's campuses, depending on the specialisation they have chosen.

About SKEMA Business School

With 9,500 students of 120 nationalities and 50,000 graduates in 145 countries, SKEMA Business School is a global school which, through its research, its +70 teaching programmes, its international multi-site structure trains and educates the talents that 21st century businesses need. The school is now present on 7 locations across 5 countries: 3 campuses in France (Lille, Sophia Antipolis, Paris), 1 in China (Suzhou), 1 in the United States (Raleigh), 1 in Brazil (Belo Horizonte) and 1 in South Africa (Cape Town - Stellenbosch).

SKEMA’s Faculty composed of 180 professors is divided into 3 academies (Globalisation, Innovation, Digitalisation). The Research Department has 5 research centres representing the main dimensions of management. The school has also established its Artificial Intelligence research and resource centre in Montreal.

SKEMA Ventures, SKEMA's incubation-acceleration dedicated device, has incubated over 250 projects.

SKEMA is multiaccredited - Equis, AACSB and EFMD Accredited EMBA. Its programmes are recognized in France (Visa, ‘licence’ Degree, Master Degree, RNCP, CGE label), as well as in the United States (Licensing), Brazil (Certificação) and China (Ministry of Education).

www.skema.edu. Follow us on Twitter: @SKEMA_BS

About EADA Business School

EADA Business School Barcelona was founded in 1957 as a private and independent institution. It has EQUIS (EFMD) and AMBA accreditations and is ranked 28th best business school in Europe by the Financial Times, top 45 best schools in Executive Education and its MBA is ranked 21st in Europe and 78th worldwide. With a renovated 4,000m2 campus in the centre of Barcelona and its residential campus in Collbató being the largest in Europe (15 hectares), today its Alumni community is represented by more than 100,000 members of 65 different nationalities and, after 64 years of history, its mission continues to be to promote the professional development and growth of people, as well as the transformation of organisations, in order to contribute to a more just, supportive and sustainable life. The axes on which it supports its learning model are innovation, sustainability and leadership.

www.eada.edu/es. Follow it on LinkedIn : @EADABusinessSchool

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts:

SKEMA Business School
Christine Cassabois
Tél +33 (0)6 27 49 36 59
Christine.cassabois@skema.edu

EADA Business School
Carlos Bascones
Tel. +34 934156262
cbascones@impart.es

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye